ALT

Altimmune Inc

Jan 30 • 04:00PM ET

5.60

+0.50 9.80 %

Healthcare • Biotechnology • USA • NASD

Peers: NVAX INO VXRT XFOR ADMA AGEN BCRX ANIX DTIL AVIR

| Held by: XBI VTI IWM VXF IBB IWO FESM VTWO IWC ITOT

Index	RUT	P/E	-	EPS (ttm)	-1.07	Insider Own	0.72%	Shs Outstand	104.34M	Perf Week	1.82%
Market Cap	701.30M	Forward P/E	-	EPS next Y	-1.21	Insider Trans	3.50%	Shs Float	103.55M	Perf Month	55.12%
Enterprise Value	506.38M	PEG	-	EPS next Q	-0.23	Inst Own	43.10%	Short Float	25.50%	Perf Quarter	40.00%
Income	-83.92M	P/S	35065.00	EPS this Y	27.16%	Inst Trans	3.65%	Short Ratio	5.46	Perf Half Y	51.76%
Sales	0.02M	P/B	2.88	EPS next Y	-23.82%	ROA	-45.82%	Short Interest	26.41M	Perf YTD	55.12%
Book/sh	1.94	P/C	3.33	EPS next 5Y	8.87%	ROE	-52.61%	52W High	7.73 -27.55%	Perf Year	-19.42%
Cash/sh	1.68	P/FCF	-	EPS past 3/5Y	17.12% 3.48%	ROIC	-41.70%	52W Low	2.90 93.10%	Perf 3Y	-60.09%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-83.45% -67.83%	Gross Margin	-495.00%	Volatility	13.69% 9.38%	Perf 5Y	-66.86%
Dividend TTM	-	EV/Sales	25319.00	EPS Y/Y TTM	31.25%	Oper. Margin	-452310.00%	ATR (14)	0.49	Perf 10Y	-90.82%
Dividend Ex-Date	-	Quick Ratio	17.18	Sales Y/Y TTM	-61.54%	Profit Margin	-419575.00%	RSI (14)	61.94	Recom	1.70
Dividend Gr. 3/5Y	- -	Current Ratio	17.18	EPS Q/Q	33.85%	SMA20	21.79%	Beta	0.10	Target Price	19.75
Payout	-	Debt/Eq	0.09	Sales Q/Q	0.00%	SMA50	19.20%	Rel Volume	1.30	Prev Close	5.10
Employees	59	LT Debt/Eq	0.08	Earnings	Nov 06 BMO	SMA200	23.04%	Avg Volume	4.83M	Price	5.60
IPO	Oct 06, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.82% 257.14%	Trades		Volume	6,280,832	Change	9.80%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Barclays	Overweight	$20
Jul-10-25	Resumed	Goldman	Sell	$1
Feb-28-25	Initiated	William Blair	Mkt Perform
Jan-08-25	Initiated	Stifel	Buy	$18
Nov-12-24	Initiated	UBS	Buy	$26
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral	$13
Mar-22-23	Downgrade	Goldman	Buy → Neutral	$20 → $6
Dec-01-22	Initiated	Goldman	Buy	$20
Dec-29-21	Resumed	Jefferies	Buy	$30
Jun-02-21	Initiated	H.C. Wainwright	Buy	$35
Feb-11-21	Initiated	Guggenheim	Buy	$36
Dec-14-20	Initiated	Jefferies	Buy	$25
Nov-12-20	Reiterated	B. Riley Securities	Buy	$31 → $28
Sep-25-20	Initiated	B. Riley FBR	Buy	$31
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight	$80
Jul-28-20	Initiated	JMP Securities	Mkt Outperform	$50
Feb-24-20	Resumed	ROTH Capital	Buy	$13
Jul-19-19	Initiated	ROTH Capital	Buy	$8.30

Show Previous Ratings

Jan-29-26 05:54PM	Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock (GlobeNewswire) +9.80%
01:31PM	Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration (PR Newswire)
Jan-28-26 04:13PM	Altimmune (ALT) Shares Slide On $75 Million Stock Offering (Benzinga) -17.15%
Jan-27-26 09:25PM	Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock (GlobeNewswire) +9.19%
Jan-23-26 02:06PM	Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly (24/7 Wall St.)
09:40AM	Loading…
09:40AM	Unusually active option classes on open January 22nd (TipRanks)
Jan-06-26 11:53AM	ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH (Zacks)
Jan-05-26 07:30AM	Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH (GlobeNewswire) +16.52%
Dec-29-25 10:15AM	3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround (Zacks)
Dec-19-25 06:30AM	Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial (GlobeNewswire) -22.77%
Dec-11-25 09:55AM	Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect? (Zacks)
Dec-01-25 07:30AM	Altimmune Announces CEO Transition and Succession Plan (GlobeNewswire) -6.27%
Nov-26-25 07:30AM	Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-25-25 09:55AM	Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know (Zacks)
Nov-11-25 08:51AM	Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting 2025 (GlobeNewswire)
06:05AM	Loading…
Nov-08-25 06:05AM	Altimmune price target lowered to $14 from $15 at Citizens JMP (TipRanks)
Nov-07-25 08:05AM	Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting 2025 (GlobeNewswire)
Nov-06-25 07:00AM	Altimmune Announces Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire) +5.07%
Nov-05-25 07:30AM	Altimmune to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Nov-03-25 07:30AM	Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder (GlobeNewswire)
Oct-31-25 11:18AM	3 Explosive Stocks With High Short Interest (24/7 Wall St.)
Oct-30-25 07:30AM	Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 (GlobeNewswire)
Oct-20-25 07:30AM	Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting 2025 (GlobeNewswire)
Oct-01-25 08:45AM	Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
Sep-30-25 10:52AM	Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights ALT (Business Wire)
Sep-29-25 07:30AM	Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide (GlobeNewswire) -5.25%
Sep-23-25 07:30AM	Altimmune to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Sep-15-25 07:30AM	Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer (GlobeNewswire)
Sep-09-25 09:00AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT (PR Newswire)
Sep-02-25 08:45AM	Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
08:45AM	Loading…
Aug-26-25 08:45AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
07:30AM	Altimmune to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-25 07:30AM	Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) (GlobeNewswire)
Aug-14-25 04:34PM	Investors in Altimmune, Inc. (ALT): Protect Your Rights - Contact Levi & Korsinsky Before October 6, 2025 (Newsfile)
Aug-13-25 04:24PM	Altimmune, Inc. (ALT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before October 6, 2025 (Newsfile)
03:07AM	Altimmune Inc (ALT) Q2 2025 Earnings Call Highlights: Strong Cash Position and Promising Drug ... (GuruFocus.com)
Aug-12-25 07:00AM	Altimmune Announces Second Quarter 2025 Financial Results and Business Update (GlobeNewswire) +7.10%
Aug-11-25 07:30AM	Altimmune Board of Directors Appoints Jerry Durso as Chairman (GlobeNewswire)
Aug-05-25 07:30AM	Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 (GlobeNewswire)
Jul-25-25 08:46AM	Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
Jul-09-25 07:30AM	Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) (GlobeNewswire)
01:19AM	Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial (Insider Monkey)
Jun-26-25 07:00AM	Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH (GlobeNewswire) -53.18%
Jun-25-25 07:12PM	Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 (GlobeNewswire) +7.23%
Jun-18-25 09:53AM	Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. (Motley Fool)
Jun-13-25 07:30AM	Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions (GlobeNewswire)
May-21-25 11:17AM	Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential (Insider Monkey)
May-19-25 07:30AM	Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) (GlobeNewswire)
May-14-25 09:18AM	Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension (TipRanks)
07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-13-25 07:00AM	Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital (GlobeNewswire)
07:00AM	Altimmune Announces First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
May-12-25 01:01PM	Will Healthy Y/Y Revenue Growth Boost Keysight's Q2 Earnings? (Zacks) +7.51%
06:33AM	Doximity Q4 Earnings Likely to Reflect Strong Product Momentum (Zacks)
May-09-25 09:55AM	How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% (Zacks)
May-08-25 07:30AM	Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress (GlobeNewswire) +8.21%
May-06-25 07:30AM	Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 (GlobeNewswire) -7.37%
May-01-25 07:30AM	Altimmune to Present at Upcoming EASL International Liver Congress 2025 (GlobeNewswire)
Apr-30-25 07:30AM	Altimmune to Participate in the Citizens Life Sciences Conference (GlobeNewswire)
04:51AM	Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? (Motley Fool)
04:51AM	Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? (Motley Fool)
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Mar-22-25 06:44AM	Buying These Dirt-Cheap Stocks Could Be a Brilliant Move (Motley Fool)
Mar-19-25 04:33PM	Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts (InsiderMonkey)
Mar-06-25 07:30AM	Altimmune to Host Virtual R&D Day on March 13, 2025 (GlobeNewswire)
Mar-03-25 07:30AM	Altimmune to Participate in the Leerink Global Healthcare Conference (GlobeNewswire) -9.92%
Feb-27-25 07:00AM	Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire) +8.08%
Feb-25-25 07:30AM	Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors (GlobeNewswire)
Feb-20-25 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 (GlobeNewswire)
Jan-29-25 07:30AM	Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-28-24 03:39PM	Jim Cramer on Altimmune, Inc. (ALT): and#8216;Healthcare Is So Out Of Fashion' (Insider Monkey)
Dec-19-24 07:30AM	Altimmune Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-17-24 08:13PM	Lightning Round: Ford's warranty problems will come back to haunt it, says Jim Cramer (CNBC TV) -6.67% -5.95%
Dec-03-24 06:22PM	Altimmune CEO on what's next for its experimental obesity drug (CNBC TV) +12.06%
Dec-02-24 07:30AM	Altimmune to Present at the Cachexia Regulatory and Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders (GlobeNewswire)
07:30AM	Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders (GlobeNewswire)
Nov-26-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-15-24 11:00AM	Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024 (GlobeNewswire) -9.99%
Nov-12-24 07:00AM	Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +29.12%
Nov-11-24 07:30AM	Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire)
07:30AM	Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-24 07:30AM	Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity (GlobeNewswire)
Nov-06-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 07:30AM	Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (GlobeNewswire)
Oct-15-24 08:00AM	Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting 2024 (GlobeNewswire) +9.49%
Oct-01-24 07:30AM	Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference (GlobeNewswire)
Sep-30-24 07:30AM	Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) (GlobeNewswire) -5.10%
Sep-10-24 01:09PM	CORRECTION Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire) +9.09%
07:45AM	Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Sep-03-24 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Aug-08-24 07:00AM	Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +15.09%
Aug-07-24 07:00AM	CytoSorbents to Report Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -7.02%
Aug-01-24 07:30AM	Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (GlobeNewswire)
Jul-25-24 07:30AM	Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology (GlobeNewswire) +6.70%
Jul-09-24 06:42AM	7 Bullish Stock Picks With the Potential to Turn $5K Into $50K (InvestorPlace)
Jul-06-24 08:00AM	The 7 Best Under $10 Stocks to Buy in July 2024 (InvestorPlace)
Jul-02-24 07:30AM	Altimmune to Participate at Leerink Partners Therapeutics Forum (GlobeNewswire) -6.39%
Jun-28-24 10:09AM	The 3 Smartest Biotech Stocks to Buy With $5K Right Now (InvestorPlace)
01:55AM	Altimmune, Inc. (ALT): Why Are Hedge Funds Shorting This Biopharmaceutical Stock? (Insider Monkey)
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey) -15.59%

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jordt Raymond M	Chief Business Officer	Jan 27 '26	Option Exercise	0.00	15,850	0	69,765	Jan 29 04:15 PM
Garg Vipin K	Director	Jan 27 '26	Option Exercise	0.00	41,200	0	420,348	Jan 29 04:10 PM
Roberts M Scot	Chief Scientific Officer	Jan 27 '26	Option Exercise	0.00	15,850	0	100,143	Jan 29 04:05 PM
Jordt Raymond M	Chief Business Officer	Jan 25 '26	Option Exercise	0.00	14,600	0	57,770	Jan 27 07:10 AM
Garg Vipin K	Director	Jan 25 '26	Option Exercise	0.00	42,050	0	397,132	Jan 27 07:05 AM
Roberts M Scot	Chief Scientific Officer	Jan 25 '26	Option Exercise	0.00	14,600	0	88,666	Jan 27 07:00 AM
Pisano Wayne	Director	Jan 08 '26	Buy	4.08	5,000	20,410	13,498	Jan 09 04:10 PM
Jordt Raymond M	Chief Business Officer	Jan 01 '26	Option Exercise	0.00	9,375	0	45,645	Jan 05 04:10 PM
Jorkasky Diane	Director	Dec 29 '25	Buy	3.80	527	2,003	527	Dec 29 04:10 PM
GILL JOHN	Director	Dec 23 '25	Buy	4.10	12,500	51,250	12,500	Dec 23 04:10 PM
Durso Jerome Benedict	Director	Dec 22 '25	Buy	4.13	12,500	51,569	12,500	Dec 22 04:10 PM
WEAVER GREGORY L	Chief Financial Officer	Nov 11 '25	Option Exercise	0.00	18,750	0	28,750	Nov 12 04:07 PM
Sohn Catherine A.	Director	Mar 17 '25	Buy	5.78	1,000	5,784	1,000	Mar 18 04:15 PM
WEAVER GREGORY L	Chief Financial Officer	Mar 13 '25	Buy	5.20	10,000	51,996	10,000	Mar 14 07:27 AM
Garg Vipin K	President and CEO	Feb 02 '25	Option Exercise	0.00	18,950	0	363,364	Feb 03 08:50 PM
Harris Matthew Scott	Chief Medical Officer	Feb 02 '25	Option Exercise	0.00	7,775	0	84,564	Feb 03 08:48 PM
Roberts M Scot	Chief Scientific Officer	Feb 02 '25	Option Exercise	0.00	7,775	0	75,536	Feb 03 08:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALT

Altimmune Inc

Upgrade your FINVIZ experience